Clinical TrialsAll subjects implanted with NPM-115 in the Phase 1 LIBERATE-1 study experienced successful implantation with no unexpected adverse events, indicating a well-tolerated procedure.
Financial StabilityThe cash balance of Vivani Medical is expected to be sufficient to fund operations into mid-2026, supporting the continuation of current studies and developments.
Product DevelopmentVivani announced positive preclinical data for NPM-139, a subdermal implant being developed for chronic weight management, which demonstrated continuous and steady semaglutide exposure.